Gilmore O’Neill

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Ludwig Kappos, Ralf Gold, David H. Miller et al. · The Lancet · 2008 · 477 citations · Full text

Relapsing-remitting Multiple Sclerosis, Medicine, Clinical Neurology +6

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Daniel Wynn, Michael D. Kaufman, Xavier Montalbán et al. · The Lancet Neurology · 2010 · 298 citations

Disease Progression, Medicine, Immunology +10

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Ralf Gold, Gavin Giovannoni, Krzysztof Selmaj et al. · The Lancet · 2013 · 285 citations

Relapsing-remitting Multiple Sclerosis, Clinical Trials, Treatment Option +7

Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes

Peter M. Andersen, Katherine B. Sims, Winnie Xin et al. · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · 2003 · 273 citations

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Ludwig Kappos, Heinz Wiendl, Krzysztof Selmaj et al. · New England Journal of Medicine · 2015 · 258 citations · Full text